Taipei, Taiwan, 24 November 2025 — Lotus Pharmaceuticals (1795:TT; “Lotus” or “the Company”), a multinational pharmaceutical company, today announced that it has received approval from the Taiwan Department of Investment Review (“DIR”) for its proposed acquisition of Alvogen US.
The approval from Taiwan DIR represents a significant regulatory clearance required for the transaction. With this milestone now secured, Lotus confirms that the acquisition remains firmly on track for completion by year end, in-line with the Company’s expectations.
In preparation for closing, Lotus will be undertaking a number of internal procedures over the coming weeks. Certain steps may require public disclosures via the Market Observation Post System (MOPS), as mandated by regulatory requirements. These are necessary procedural steps to ensure a smooth and timely closing of the transaction before the end of 2025.
Leadership Comments
Petar Vazharov, Chief Executive Officer of Lotus Pharmaceuticals, commented:
“Approval from Taiwan DIR marks a critical milestone in the acquisition of Alvogen US, and we appreciate the regulator’s thorough and timely review. With this key clearance obtained, we are progressing confidently toward closing by year end. This acquisition will significantly expand our scale and strengthen Lotus’ position as a leading specialty pharmaceutical company across global markets.”
About Lotus
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness
Media Inquiries:
Yihsuan Kuo, Investor Relations Assistant Manager
Jeffrey Tsang, Head of Investor Relations and Corporate Communications
+886 2 2700 5908
investor@lotuspharm.com